Project title: POLYSACCHARIDE DERIVATIVES

Company name : CONJUGATE LTD.

TECHNOLOGICAL FIELD
Conjugated Drugs & Antiinfection
Drugs

KEY WORDS
Polysaccharides,
Arabinoglactan, Amphotericine B, Fungal Infections. Conjugated
Drugs, Drug Delivery

PROJECT SUMMARY
The Company has developed a unique platform technology involving
polymer-drug conjugates designed to improve the safety and
efficacy of clinically-used small drug molecules. The Company's
technology can be applied to many drugs, offering specific
critical enhancement for each conjugated drug.
The Company's first product is an antifungal therapy for acute
invasive fungal infections in patients with compromised immune
systems. The novel treatment is a next-generation,
broad-spectrum, injectable antifungal based on Amphotericin B, a
drug known to be highly efficacious, yet extremely toxic.
ConjuGate's unique proprietary technology allows for the
preservation of the drug's efficacy while dramatically reducing
its toxicity.

ADVANTAGES
The platform technology and the new drug has several advantages
over the
existing AmB formulations: higher solubility, lower toxicity and
higher target tissue
concentration, providing better therapeutic effect. ConjuGate's
unique proprietary technology allows for the preserving of the
drug's efficacy while dramatically reducing its toxicity.

MARKETS
The Company's new drug will potentially serve an estimated 9
million patients across seven major markets who are considered
`at risk' for invasive fungal infections, with approximately 1.2
million per year actually affected (2003 estimates).
Fungal infections are becoming a serious public-health hazard,
particularly due to the increasing incidence of life-threatening
fungal infections in immunocompromised hosts such as cancer
patients, patients after transplantation and patients with AIDS.
The total market value of systemic antifungal drugs was estimated
to reach as much as 5 billion $ in 2014 (Data monitor may 2004).
The estimated market share for ConjuGate's Antifungal drug is
expected to be as high as 1 billion $ of the total systemic
antifungal market.

ENTREPRENEURS
Prof. Itzhack Polacheck - Chief Technologist,
Head of the Department of Clinical Microbiology & Infectious
Diseases, Hadassah Medical Center.
Prof. Abraham Domb - Scientific
Consultant, Head of the Department of Medicinal Chemistry, School
of Pharmacy, The Hebrew University.
Ms. Hagit Sepkuty - The company
manager.

PROJECT STATUS
The company was established in November 2005.
Safety and efficacy had been proven in several animal models.
Production process and QC methods have been finalized. A formal
Pre-IND meeting with the FDA was held during July 2006 -
Regulatory Path is clear. Pilot Production Up Scale.
Pre clinical studies will be completed during 2007.

COOPERATION REQUIRED
The company is looking for strategic partners for the preclinical
& clinical trials.
The company is looking for further investment for the clinical
trials and for further development of more products.

Request for more information, about this project.

Note - you have to be registered in this server to request information. If you haven't done so yet, please:
Register in this server and your requests will be forwarded to the developer, who will contact you directly

List of projects that you already requested more information about